A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions
A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
Inclusion Criteria:
Informed Consent
BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)
70 years of age or less
Have 2 or more of the following obesity-related co-morbid conditions:
Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (<200 mg/dL)
At lease one of the following metabolic criteria:
Waist circumference ≥ 102 cm for men or ≥88 cm for women
Exclusion Criteria: